About Iktos
Iktos is a pioneering AI and robotics company transforming drug discovery through fully integrated automation. Founded in 2016 and headquartered in Paris, France, Iktos has developed a comprehensive platform that combines generative AI, retrosynthesis planning, and robotic automation to accelerate the drug discovery process. The company's flagship product, Makya, is a generative AI SaaS platform designed by chemists for chemists that creates diverse, novel, and synthetically accessible molecules optimized for drug development. Spaya, their AI-driven retrosynthesis platform, rapidly identifies feasible synthetic routes by converting target compounds into commercially available starting materials in seconds. Iktos Robotics completes the ecosystem by managing the entire synthetic process through automated workflows, from ordering raw materials to executing chemical synthesis, purification, analysis, and biological testing. The platform enables a fully digitized, AI-driven Design-Make-Test-Analyze (DMTA) cycle that significantly reduces drug discovery timelines to under 24 months. Iktos serves pharmaceutical companies, biotech firms, and academic institutions, having completed over 60 collaborations since inception. The company maintains an in-house pipeline targeting areas including inflammation, auto-immune diseases, obesity, metabolism, and immuno-oncology. Iktos has been recognized with a prestigious European Innovation Council (EIC) Accelerator grant for its groundbreaking work integrating generative AI, robotics, and high-precision biological screening.
Mission & Story
Mission
Drug Discovery as it will be - Pioneering AI and Robotics in Drug Discovery to transform drug discovery by integrating the creativity of Generative AI with automated synthesis and testing, forging a path towards fully autonomous labs, accelerating the development of new treatments to improve patient care.
Clinical Focus
Medical conditions and clinical areas addressed by Iktos.
Who It Serves
Milestones & Awards
Recent Milestones
Makya 2.0 launch with new data analysis and visualization experience (2026); Partnership with Chemspeed announced (March 2026); Pierre Fabre Laboratories collaboration announced (January 2026); Iktos Engine APIs for Agentic workflows launched (May 2026); New ligand-based design models released (January 2026)
Awards & Recognition
European Innovation Council (EIC) Accelerator grant recipient
Key Partnerships
Company Details
- Founded
- 2016
- Headquarters
- Paris, Île-de-France, France
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.